Antimonial treatment failure rate in patients with cutaneous leishmaniasis

Antimonial treatment failure rate in patients with cutaneous leishmaniasis

Results: Rate of treatment failure with Meglusan was 4.3%. Failure rate in men and in patients with previous history of cutaneous leishmaniasis was more than women or patients without CL history (P= 0.000, 0.024 respectively). The results of this study showed that treatment failurewas higher in patients with systemic treatment than intralesional (IL) or combination therapy (both IL and systemic treatment) group but this difference was not statistically significant. Also, size and number of the lesions, wound infection, the patient’s age, location, education and occupation do not have a significant correlation with treatment failure
Conclusion: Greater treatment failure rate of Meglusan compared to Glucantime (4.3% versus< 1%, respectively) is an important issue to be considered in CL therapeutic strategy

Related Article

Leave a Reply

Your email address will not be published. Required fields are marked *